Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-04-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2021年度独立董事述职报告
Regulatory Filings
2022-04-27 Chinese
安旭生物2021年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2021年度业绩快报公告" which translates to "2021 Annual Performance Express Announcement." It contains preliminary financial data for the year 2021, including revenue, profit, and asset figures, but explicitly states that the data is unaudited and that the final audited data will be in the company's 2021 Annual Report. The document is relatively short (1928 characters) and serves as a preliminary earnings summary rather than a full comprehensive report. It does not contain full financial statements or detailed analysis, but rather highlights key financial metrics and performance indicators. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is ER with high confidence. FY 2021
2022-02-25 Chinese
安旭生物控股股东及实际控制人关于杭州安旭生物科技股份有限公司股票交易异常波动的问询函的回函
Regulatory Filings
2022-02-09 Chinese
安旭生物股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Hangzhou Anxu Biotechnology Co., Ltd. It details the unusual price movements of the company's stock over two trading days, confirms no undisclosed material information, and provides risk warnings to investors. It references stock exchange trading rules and regulatory requirements but does not contain financial statements, earnings data, or management discussion. The document is short (1591 characters) and serves as a regulatory disclosure about stock price volatility rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-02-09 Chinese
上海市锦天城律师事务所关于杭州安旭生物科技股份有限公司2022年第一次临时股东大会法律意见书
Regulatory Filings
2022-01-28 Chinese
安旭生物关于公司全资子公司开立募集资金专用账户并签署募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for raised funds by a wholly-owned subsidiary and the signing of a four-party supervision agreement related to the use and management of these funds. It details the background of the fundraising, the approval by the China Securities Regulatory Commission, the amount raised, and the regulatory compliance measures taken, including the signing of agreements with the bank and sponsor. The document does not contain financial statements or detailed financial performance data but rather focuses on the procedural and regulatory aspects of fund management and supervision. The length is about 3,058 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it relates to the management and use of capital raised through a public offering and the associated regulatory agreements.
2022-01-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.